Orchestra BioMed Announces Pricing of $40 Million Public Offering
1. Orchestra BioMed offers 9.4 million shares at $2.75 each. 2. Gross proceeds aimed at developing AVIM therapy and Virtue SAB. 3. Collaboration with Medtronic boosts potential for AVIM therapy. 4. Four Breakthrough Device Designations received for current programs. 5. Offering expected to close on August 4, 2025.